Aducanumab-avwa is a monoclonal antibody that is the first treatment of its class designed to target the amyloid β protein, a biomarker of Alzheimer disease and other dementias.
Nicholas C Smith, Tanae’Ja C Burroughs, Patric H Gaspard, Nandi P Okonkwo, Duy P Tran, Phyllisity V Walters, PharmD Candidates; Jocelyn D. Spates, PharmD, BCPS
Advertisement
Articles by Nicholas C Smith, Tanae’Ja C Burroughs, Patric H Gaspard, Nandi P Okonkwo, Duy P Tran, Phyllisity V Walters, PharmD Candidates; Jocelyn D. Spates, PharmD, BCPS
Advertisement
Latest Updated Articles
New Drug Overview: Aducanumab-Avwa (Aduhelm) for Alzheimer DiseasePublished: November 4th 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Recognizing Immunizing Pharmacists in the Community
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
PCV20 Demonstrates Real-World Effectiveness Against Pneumonia in Older Adults
5
